Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

prestige brands (uk) ltd - sodium cromoglicate - eye drops - 20mg/1ml

Irland - engelska - HPRA (Health Products Regulatory Authority)

rayner pharmaceuticals limited - sodium cromoglicate - eye drops, solution - 2 percent weight/volume - other antiallergics; cromoglicic acid

Irland - engelska - HPRA (Health Products Regulatory Authority)

bausch health ireland limited - sodium cromoglycate - eye drops, solution - 2 percent weight/volume - other antiallergics; cromoglicic acid

Irland - engelska - HPRA (Health Products Regulatory Authority)

bausch + lomb ireland limited - sodium cromoglycate - eye drops, solution - other antiallergics; cromoglicic acid

Malta - engelska - Medicines Authority

sanofi malta limited - cromoglicate sodium - eye drops, solution - cromoglicate sodium 2 % (w/v) - ophthalmologicals

Australien - engelska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - latanoprost, quantity: 50 microgram/ml; timolol maleate, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; monobasic sodium phosphate monohydrate; water for injections; sodium hydroxide; dibasic sodium phosphate; hydrochloric acid; sodium chloride - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanoprost/timolol eye drops should not be used to initiate therapy.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml; timolol maleate, quantity: 6.8 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; purified water; hydrochloric acid - combigan eye drops are indicated for the reduction of elevated intraocular pressure for treatment of open angle glaucoma and/or ocular hypertension, in patients not adequately responding to monotherapy

Australien - engelska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium chloride, quantity: 9 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; disodium edetate; water for injections - ophthalmic irrigating agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium chloride, quantity: 50 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; disodium edetate; water for injections - for use in the management of oedematous states of the cornea.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.